John B Moriarty
CIK 1564621 · Chief Legal Officer · last filed 2026-06-22
John B Moriarty is a Chief Legal Officer who has filed 58 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing, for KARD, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$252.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $953.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$953.6K
6
58
-$252.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Chief Legal Officer | 47,784 | — | — | $0 | 1 | 2026-06-22 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Chief Legal Officer | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | Chief Legal Officer | 74,557 | $12.79 | $953.6K | -$252.8K | 5 | 2026-01-09 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Legal Officer | 0 | $58.70 | $0 | $0 | 2 | 2024-01-23 |
| OLMA | EVP, Ch. Legal Officer & Sec. | — | $10.52 | — | $0 | 3 | 2023-02-02 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | EVP, General Counsel | 0 | — | — | $0 | 7 | 2020-07-02 |
Recent Filings
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | KARD | Grant (A) | +47,784 | $0 | EDGAR |
| 2026-02-27 | Avidity Biosciences, Inc. (RNAM) Delisted | Disp (D) | −92,054 | $0 | EDGAR |
| 2026-01-09 | RNA | Sell (S) | −2,374 | -$171.5K | EDGAR |
| 2025-12-19 | RNA | Mixed | +29,176 | -$1.93M | EDGAR |
| 2025-08-05 | RNA | Sell (S) | −2,245 | -$81.3K | EDGAR |
| 2025-01-08 | RNA | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-08-05 | RNA | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-01-23 | Mirati Therapeutics, Inc. (MRTX) Delisted | Disp (D) | −72,335 | $0 | EDGAR |
| 2023-08-10 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +22,297 | $825.0K | EDGAR |
| 2023-07-20 | OLMA | Notice (144) | −5,265 | -$48.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.